Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Enterprise Technology
  • Contract Manufacturing
  • R&D 100 Awards

Pharma Execs Face the Feds

By MaryBeth DiDonna | March 26, 2019

The leaders of seven major pharmaceutical companies have been called to testify before the Senate Finance Committee, on the topic of drug prices. The committee is led by Senators Chuck Grassley of Iowa and Ron Wyden of Oregon, who argue that prescription drug costs have climbed too high and the rate at which prices are increasing is “unsustainable.” Unlike other countries, American drugmakers do not negotiate drug prices with the federal government.

The CEOs of AbbVie, AstraZeneca, Bristol-Myers Squibb, Merck, Pfizer and Sanofi, as well as Johnson & Johnson’s company group chairperson for pharmaceuticals in the Americas, have been sent to Capitol Hill to speak to lawmakers about this issue. These seven companies have a collective market value of $1.13 trillion.

Many pharmaceutical companies have blamed pharmacy benefit managers—those who negotiate discounts with the manufacturers—for increases in prescription drug costs, and also say that price cuts could affect their companies’ R&D initiatives and the development of new treatments for disease and illness. During the Congressional hearing, the pharma executives pointed out that rebates play a role in high prescription drug prices, and the Trump administration has pitched a proposal that would abolish certain rebates drug makers pay insurance companies in Medicare, in an effort to lower prices.

Pfizer CEO Albert Bourl touted his company’s advancements in the treatment of breast and lung cancers, as well as leukemia, meningitis B and the development of a non-opioid pain treatment. “All of these breakthroughs won’t do anyone any good if patients can’t afford them,” Bourla said. “Our healthcare system is broken, and we need to fix it.”

Senator Grassley countered with, “We’ve all seen the finger-pointing. Every link in the supply chain has gotten skilled at that … but like most Americans, I’m sick and tired of the blame game. It’s time for solutions.” Senator Wyden added that drug prices in the U.S. “did not become outrageously expensive by accident” but are “astronomically high because that’s where pharmaceutical companies and their investors want them.”

Both the White House and the House of Representatives’ Democratic majority have addressed the need to get drug pricing under control, making it a rare bipartisan issue in Washington. The situation is certainly frustrating and complex, and will take serious work and cooperation to solve.

Related Articles Read More >

HIV
Injectable anti-HIV therapies could see strong growth
Pfizer-BioNTech vaccine
Pfizer vaccine stable at standard freezer temps, effective with single dose
coronavirus COVID-19 Pfizer
4 things to keep in mind as COVID-19 vaccination efforts scale
Johnson & Johnson
J&J CEO says getting a COVID-19 vaccine could be an annual ritual for years

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Pharmaceutical Processing World
  • Enews Signup
  • Contact Us
  • About Us
  • R&D World
  • DeviceTalks
  • Drug Discovery & Development
  • Drug Delivery Business News
  • MassDevice
  • Medical Design Sourcing

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Enterprise Technology
  • Contract Manufacturing
  • R&D 100 Awards